Compare NAT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAT | REPL |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | Bermuda | United States |
| Employees | 18 | 465 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.2B |
| IPO Year | 1997 | 2018 |
| Metric | NAT | REPL |
|---|---|---|
| Price | $8.00 | $12.94 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 2 | 9 |
| Target Price | $4.00 | ★ $5.67 |
| AVG Volume (30 Days) | ★ 4.5M | 1.9M |
| Earning Date | 05-28-2026 | 05-21-2026 |
| Dividend Yield | ★ 8.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $77.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $525.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.06 | $1.50 |
| 52 Week High | $8.33 | $16.33 |
| Indicator | NAT | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 68.21 | 43.52 |
| Support Level | $5.42 | $12.40 |
| Resistance Level | N/A | $16.02 |
| Average True Range (ATR) | 0.28 | 0.72 |
| MACD | 0.08 | -0.34 |
| Stochastic Oscillator | 75.80 | 15.14 |
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.